Sarbecovirus

Living History: Our Role in Global Scientific Collaboration for SARS-CoV-2, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, May 27, 2021
Bat virome, Sarbecovirus, Severe acute respiratory syndrome, Infectious diseases, Medical specialties, Animal diseases

It was through science virology, immunology, cellular immunology and the worldwide collaborative effort that a vaccine was approved and made commercially available in 314 days.

Key Points: 
  • It was through science virology, immunology, cellular immunology and the worldwide collaborative effort that a vaccine was approved and made commercially available in 314 days.
  • This webinar will pull back the curtain on partnering with the biopharmaceutical industry for vaccine development as a world class specialty laboratory.
  • For more information, or to register for this event, visit Living History: Our Role in Global Scientific Collaboration for SARS-CoV-2.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.

TrippBio announces publication of data supporting the antiviral potency of TD-213 against SARS-CoV-2

Retrieved on: 
Wednesday, May 26, 2021
Biocides, Sarbecovirus, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Antiviral drugs, Gilead Sciences

The manuscript entitled "Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro" describing the antiviral profile of TD-213 is available on an online preprint server at https://www.biorxiv.org/content/10.1101/2021.05.21.445119v1 is undergoing scientific peer-review for potential publication.

Key Points: 
  • The manuscript entitled "Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro" describing the antiviral profile of TD-213 is available on an online preprint server at https://www.biorxiv.org/content/10.1101/2021.05.21.445119v1 is undergoing scientific peer-review for potential publication.
  • These results will be used to design appropriate clinical trials to evaluate the efficacy of TD-213 as a treatment for mild-to-moderate COVID-19.
  • "We are pleased to finally be able to share these exciting data on the antiviral potency of TD-213 against the SARS-CoV-2 virus," said David E. Martin, PharmD, CEO.
  • We are currently planning our proof-of-concept study and look forward to reviewing the clinical data when available."

Sixth Wave Partners with ACAMP to Develop RFID Enabled Virus Detection Products Utilizing AMIPs(TM)

Retrieved on: 
Tuesday, May 25, 2021
Sarbecovirus, Respiratory diseases, Zoonoses, Animal diseases, Bat virome, Severe acute respiratory syndrome, COVID-19

SIXW is engaging ACAMP for their expertise in RF technology with the goal of pairing the technology with AMIPs.

Key Points: 
  • SIXW is engaging ACAMP for their expertise in RF technology with the goal of pairing the technology with AMIPs.
  • ACAMP facilities have over 14,000 square feet of lab space and house over $15 million in specialized product development equipment.
  • Offering unparalleled access to world-class engineering expertise, and advanced design, analysis, testing and manufacturing equipment, ACAMP can provide support at every stage of development.
  • AMIPs is a leading-edge detection platform that uses synthetic polymers to swiftly detect viruses such as the SARS-CoV-2 virus that causes COVID-19.

Waters Introduces the SARS-CoV-2 LC-MS Kit (RUO) to Advance Clinical Research of Infectious Diseases

Retrieved on: 
Tuesday, May 25, 2021
Biotechnology, Infectious diseases, Health, Science, Research, Sarbecovirus, Zoonoses, Animal diseases, Respiratory diseases, Ruo, Severe acute respiratory syndrome

Waters Corporation (NYSE:WAT) today introduced a new RUO LC-MS test method to advance critical infectious disease research.

Key Points: 
  • Waters Corporation (NYSE:WAT) today introduced a new RUO LC-MS test method to advance critical infectious disease research.
  • Waters SARS-CoV-2 LC-MS Kit (RUO) uses an orthogonal analytical method that directly detects and quantifies SARS-CoV-2 Nucleocapsid (NCAP) peptides that initial studies have shown to yield highly accurate, quantitative results.
  • Waters developed the SARS-CoV-2 LC-MS Kit (RUO) in support of a coalition of academic, commercial and government research scientists1.
  • This kit is for research use only and has not been approved for use in clinical diagnostic procedures.

Labcorp Study Suggests COVID-19 Antibodies Remain at Least 10 Months After Infection

Retrieved on: 
Monday, May 24, 2021
MEN, Medical devices, Infectious diseases, Hospitals, Family, Genetics, Consumer, Clinical trials, Cardiology, Diabetes, Biotechnology, AIDS, Health, Women, Pharmaceutical, Seniors, Oncology, Sarbecovirus, Medical specialties, Health, Medicine, Virology, Zoonoses, Bat virome, Peplomer, COVID-19, LabCorp, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

Nearly 87% of naturally infected COVID-19 patients maintained antibodies to SARS-CoV-2 proteins for at least 10 months, according to a new Labcorp (NYSE: LH) analysis of specimens from 39,086 individuals.

Key Points: 
  • Nearly 87% of naturally infected COVID-19 patients maintained antibodies to SARS-CoV-2 proteins for at least 10 months, according to a new Labcorp (NYSE: LH) analysis of specimens from 39,086 individuals.
  • Our observational analysis provides an encouraging timeline for antibody development and sustainability among the U.S. population, said David Alfego, PhD, Labcorp senior data scientist and the papers lead author.
  • We sincerely hope it sparks more research, helps unearth answers to complex questions and informs critical, post-pandemic planning.
  • Alfego and a team of Labcorp scientists analyzed results from tests used to detect antibodies that guard against spike and nucleocapsid proteins on the SARS-CoV-2 virus.

ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing

Retrieved on: 
Thursday, May 20, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious diseases, Clinical trials, Sarbecovirus, Zoonoses, Animal diseases, Respiratory diseases, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, IPA’s PolyTope Platform, ImmunoPrecise Antibodies Ltd., IPA’S POLYTOPE PLATFORM, IMMUNOPRECISE ANTIBODIES LTD.

To our knowledge, this is the first publicly reported study demonstrating in vivo synergistic effects in SARS-CoV-2 infected animals using a dose-escalation study.

Key Points: 
  • To our knowledge, this is the first publicly reported study demonstrating in vivo synergistic effects in SARS-CoV-2 infected animals using a dose-escalation study.
  • In IPA\xe2\x80\x99s preclinical study:\nIPA\xe2\x80\x99s TATX-03b PolyTope antibody cocktail was administered as a single dose to hamsters that had been infected with SARS-CoV-2 mutant D614G.
  • TATX-03b is highly efficacious, clearing replication-competent viral titer to undetectable levels in the lung in 100% (five out of five) animals.
  • \xe2\x80\x9cThese variants will continue to create a moving target for vaccines and therapeutics that were not rationally designed to withstand the emergence of novel variants and strains.

Global is Going Mobile; Global WholeHealth Partners Corp (GWHP-OTC) has Signed an Agreement With Dr. Vu Le to be the Medical Director for the CLIA WAIVED Mobile Laboratory

Retrieved on: 
Thursday, May 20, 2021
Variants of SARS-CoV-2, Medical specialties, Branches of biology, Zoonoses, Health, Sarbecovirus, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, Peplomer, Virus, Severe acute respiratory syndrome coronavirus, Antibody

Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.

Key Points: 
  • Global WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses.
  • The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein.
  • Investors and security holders are urged to read these documents free of charge on the SEC\'s web site at http://www.sec.gov .
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\n'

ECDC releases new dashboard on SARS-CoV-2 variants

Retrieved on: 
Thursday, May 20, 2021
Coronaviridae, Variants of SARS-CoV-2, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, Lineage B.1.617, Severe acute respiratory syndrome coronavirus, Lineage B.1.1.7

Data for the most recent reporting week have been excluded, as they may be incomplete.

Key Points: 
  • Data for the most recent reporting week have been excluded, as they may be incomplete.
  • The proportion of variants is only reliable when sequencing capacity is adequate (500 or 10% of total samples).
  • For TESSy data, no proportion of variants has been estimated where there is no reliable denominator available.
  • In addition, SARS-CoV-2 lineages B.1.617.1, B.1.617.2, and B.1.617.3, first reported in India in December 2020, have been increasingly detected in other countries.

Preliminary results suggest nearly 6% of Montreal children tested from October to April had antibodies to SARS-CoV-2

Retrieved on: 
Tuesday, May 18, 2021
Sarbecovirus, Medical specialties, Respiratory diseases, Health sciences, Occupational safety and health, Atypical pneumonias, Epidemiology, Serology, Seroprevalence, Severe acute respiratory syndrome coronavirus, COVID-19, Severe acute respiratory syndrome

As an overall average, 5.8% of participating children were found to have antibodies to SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • As an overall average, 5.8% of participating children were found to have antibodies to SARS-CoV-2, the virus that causes COVID-19.
  • By April 2021, in the third wave, 8.9% of the students tested had antibodies.
  • \xe2\x80\x9cThe results also suggest that seroprevalence is higher in neighbourhoods with lower socio-economic indexes and at a greater percentage for racialized residents.
  • The blood samples were taken from 354 children in daycare, 725 children in elementary schools, and 553 students in high schools.

Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)

Retrieved on: 
Tuesday, May 18, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical specialties, Zoonoses, Sarbecovirus, Medicine, Clinical medicine, Variants of SARS-CoV-2, XC2, Lineage B.1.1.7, COVID-19, Severe acute respiratory syndrome coronavirus, Monoclonal antibody

CT-P59 is known to successfully neutralise the SARS-CoV-2 variants first identified in the UK (B.1.1.7), California (B.1.427/B.1.429), Brazil (P.2), in addition to the previously identified six variant genome mutations of SARS-CoV-2 (variants S\xc2\xb7L\xc2\xb7V\xc2\xb7G\xc2\xb7GH\xc2\xb7GR).\n\xe2\x80\x9cThe emergence of SARS-CoV-2 variants has created great concern across the globe.

Key Points: 
  • CT-P59 is known to successfully neutralise the SARS-CoV-2 variants first identified in the UK (B.1.1.7), California (B.1.427/B.1.429), Brazil (P.2), in addition to the previously identified six variant genome mutations of SARS-CoV-2 (variants S\xc2\xb7L\xc2\xb7V\xc2\xb7G\xc2\xb7GH\xc2\xb7GR).\n\xe2\x80\x9cThe emergence of SARS-CoV-2 variants has created great concern across the globe.
  • \xe2\x80\x9cMonoclonal antibodies have the potential to alleviate symptoms and prevent progression to severe disease in patients with mild to moderate COVID-19.
  • Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries.
  • For more information please visit: https://www.celltrionhealthcare.com/en-us .\nCT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus.